Denosumab biosimilar is under clinical development by Biocon and currently in Phase I for Osteoporosis. According to GlobalData, Phase I drugs for Osteoporosis have a 66% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Denosumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Denosumab biosimilar overview
Denosumab is under development for the treatment of osteoporosis, unspecified cancer, osteoporosis in post-menopausal women who are at high-risk for fracture and preventing bone fracture in patients with multiple myeloma and preventing bone metastases from solid tumors.
Biocon is a biopharmaceutical company that focuses on the research and development of therapies for the treatment of chronic conditions such as cancer, diabetes and autoimmune diseases. It offers a range of active pharmaceutical ingredients (APIs), branded formulations, complex biologics and biosimilars including monoclonal antibodies (MAbs), rh-Insulin and insulin analogs. The company also provides services including contract manufacturing, drug licensing, research, development and manufacturing of small and large molecules for biotechnology and pharmaceutical companies across the world. It has a manufacturing facility and R&D center at BioXcell, Malaysia. It operates overseas offices in the UK, Ireland, the US, Switzerland, Dubai, and Malaysia. Biocon is headquartered in Bangalore, Karnataka, India.
For a complete picture of Denosumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.